[Urology] How should premature ejaculation be treated?

Early ejaculation—more accurately termed premature ejaculation (PE)—is a common sexual health concern characterized by persistent or recurrent ejaculation occurring with minimal sexual stimulation, either before or shortly after penetration, and before the individual desires it. Diagnosis typically requires that this pattern persists for at least six months and causes clinically significant distress or interpersonal difficulty.

Treatment is individualized and evidence-based, beginning with a thorough evaluation to rule out underlying contributors such as hormonal imbalances (e.g., low testosterone or elevated prolactin), thyroid dysfunction, genitourinary infections (e.g., prostatitis), neurological conditions, or psychiatric comorbidities like anxiety or depression. Lifestyle factors—including excessive alcohol use, smoking, sedentary behavior, and poor sleep hygiene—should also be assessed and addressed.

First-line management often includes behavioral techniques, such as the “start-stop” and “squeeze” methods, which aim to improve ejaculatory control through increased awareness and modulation of arousal. Psychosexual counseling—either individually or with a partner—is highly recommended, particularly when PE is linked to performance anxiety, relationship stress, or early negative sexual experiences.

Pharmacotherapy is supported by robust clinical evidence. On-demand selective serotonin reuptake inhibitors (SSRIs) like dapoxetine (the only SSRI approved globally for PE) are commonly prescribed due to their rapid onset and favorable tolerability profile. Off-label daily SSRIs—including sertraline, paroxetine, or fluoxetine—may also be effective but require careful monitoring for side effects such as decreased libido or fatigue. Topical anesthetics (e.g., lidocaine–prilocaine cream) applied 15–30 minutes before intercourse can reduce penile sensitivity; however, proper application and partner desensitization precautions are essential to avoid numbness-related dissatisfaction.

In select cases—particularly when PE coexists with erectile dysfunction—phosphodiesterase type 5 inhibitors (e.g., sildenafil or tadalafil) may be considered adjunctively. Emerging options, including tramadol (a dual-action opioid–serotonin–norepinephrine agent), show promise in refractory cases but carry regulatory and safety considerations requiring specialist oversight.

Patients should be reassured that PE is highly treatable, and successful outcomes often involve a multimodal approach combining education, behavioral strategies, psychological support, and targeted pharmacotherapy. Referral to a urologist or sexual medicine specialist is appropriate when first-line interventions fail, symptoms are severe or sudden-onset, or when comorbid urological conditions are suspected.